 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
 |
 |
|
Pharmacodynamics
of telithromycin
|
|
|
(as
based on FDA submission; april 2001)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
|
|
Organism MIC90
|
|
|
S. pneumoniae < 0.008 - 0.25
|
|
S. pyogenes < 0.015 - 0.06
|
|
H.
influenzae 2.0 - 4.0
|
|
|
M. catarrhalis 0.12
|
|
|
L. pneumophila
0.03 - 0.12
|
|
|
C. pneumoniae
0.03 - 2
|
|
|
M. pneumoniae 0.25
|
|
|
|
|
|
 |
 |
 |
 |
Cmax/MIC90max AUC24h/MIC90max
|
|
7.6 33.2
|
|
|
31.6 138
|
|
|
0.475 2.075
|
|
|
15.8 69.1
|
|
|
|
|
|
|
|
 |
 |
 |
Activity will
be good for
|
|
MIC£ 0.25 mg/L,
but may
|
|
become
problematic for
|
|
|
higher MICs
|
|
|
|
|
|
|
|
http://www.fda.gov/ohrms/dockets/ac/01/slides/3746s_09_aventis/
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|